Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells

REFERENCES

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
   PubMed Web of Science ®Google Scholar
• Bilici A. Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol 2014;20(14):3905–3915.
   PubMed Web of Science ®Google Scholar
• Khromova N, Kopnin P, Rybko V, Kopnin BP. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012;31(11):1389–1397.
   PubMed Web of Science ®Google Scholar
• Lee E, Koskimaki JE, Pandey NB, Popel AS. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Neoplasia 2013;15(2):112–124.
   PubMed Web of Science ®Google Scholar
• Roberts N, Kloos B, Cassella M, Podgrabinska S, Persaud K, Wu Y, Pytowski B, Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 2006;66(5):2650–2657.
   PubMed Web of Science ®Google Scholar
• Alam A, Blanc I, Gueguen-Dorbes G, Duclos O, Bonnin J, Barron P, Laplace MC, Morin G, Gaujarengues F, Dol F, Herault JP, Schaeffer P, Savi P, Bono F. SAR131675, a potent and selective VEGFR-3-TK inhibitor with antilymphangiogenic, antitumoral, and antimetastatic activities. Mol Cancer Ther 2012;11(8):1637–1649.
   PubMed Web of Science ®Google Scholar
• Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou CH, Jeng YM, Wang MY, Chang KJ, Hung MC, Kuo ML. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006;9(3):209–223.
   PubMed Web of Science ®Google Scholar
• Liu XE, Sun XD, Wu JM. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol 2004;10(3):352–355.
   PubMed Web of Science ®Google Scholar
• Han FH, Zhan WH, He YL, Li YM, Zheng ZQ, Peng JS, Cai SR, Ma JP. The expression of VEGF-C, VEGFR-3 and its predictive value on lymph node metastasis and prognosis of gastric cancer. Zhonghua Wai Ke Za Zhi 2006;44(15):1058–1061.
   PubMedGoogle Scholar
• Yuanming L, Feng G, Lei T, Ying W. Quantitative analysis of lymphangiogenic markers in human gastroenteric tumor. Arch Med Res 2007;38(1):106–112.
   PubMed Web of Science ®Google Scholar
• Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer 2010;10:299.
   PubMed Web of Science ®Google Scholar
• Amioka T, Kitadai Y, Tanaka S, Haruma K, Yoshihara M, Yasui W, Chayama K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur J Cancer 2002;38(10):1413–1419.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer 2013;13(12):871–882.
   PubMed Web of Science ®Google Scholar
• Lee GW, Park HS, Kim EJ, Cho YW, Kim GT, Mun YJ, Choi EJ, Lee JS, Han J, Kang D. Reduction of breast cancer cell migration via up-regulation of TASK-3 two-pore domain K+ channel. Acta Physiol (Oxf) 2012;204(4):513–524.
   PubMed Web of Science ®Google Scholar
• Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K, Sueishi K. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol 2009;175(4):1709–1721.
   PubMed Web of Science ®Google Scholar
• Qin XJ, Dai DJ, Gao ZG, Huan JL, Zhu L. Effect of lentivirus-mediated shRNA targeting VEGFR-3 on proliferation, apoptosis and invasion of gastric cancer cells. Int J Mol Med 2011;28(5):761–768.
   PubMed Web of Science ®Google Scholar
• Kodama M, Kitadai Y, Tanaka M, Kuwai T, Tanaka S, Oue N, Yasui W, Chayama K. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res 2008;14(22):7205–7214.
   PubMed Web of Science ®Google Scholar
• Shida A, Fujioka S, Kobayashi K, Ishibashi Y, Nimura H, Mitsumori N, Yanaga K. Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma. Int J Clin Oncol 2006;11(1):38–43.
   PubMedGoogle Scholar
• Yonemura Y, Fushida S, Bando E, Kinoshita K, Miwa K, Endo Y, Sugiyama K, Partanen T, Yamamoto H, Sasaki T. Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer. Eur J Cancer 2001;37(7):918–923.
   PubMed Web of Science ®Google Scholar
• Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Hocker M. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006;24(2):228–240.
   PubMed Web of Science ®Google Scholar
• Yashiro M, Shinto O, Nakamura K, Tendo M, Matsuoka T, Matsuzaki T, Kaizaki R, Ohira M, Miwa A, Hirakawa K. Effects of VEGFR-3 phosphorylation inhibitor on lymph node metastasis in an orthotopic diffuse-type gastric carcinoma model. Br J Cancer 2009;101(7):1100–1106.
   PubMed Web of Science ®Google Scholar
• Chen FZ, Mo XM, Wang QP, Li J, Zhang L. Effects of rosiglitazone on the growth and lymphangiogenesis of human gastric cancer transplanted in nude mice. Oncol Rep 2013;30(6): 2705–2712.
   PubMed Web of Science ®Google Scholar
• Schaeffer D, Somarelli JA, Hanna G, Palmer GM, Garcia-Blanco MA. Cellular migration and invasion uncoupled: increased migration is not an inexorable consequence of epithelial-to-mesenchymal transition. Mol Cell Biol 2014;34(18):3486–3499.
   PubMed Web of Science ®Google Scholar
• Yeudall WA, Miyazaki H, Ensley JF, Cardinali M, Gutkind JS, Patel V. Uncoupling of epidermal growth factor-dependent proliferation and invasion in a model of squamous carcinoma progression. Oral Oncol 2005;41(7):698–708.
   PubMed Web of Science ®Google Scholar
• Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, Knudsen BS, Hay R, Shinomiya N, Vande Woude GF. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci U S A 2005;102(30):10528–10533.
   PubMed Web of Science ®Google Scholar
• Alitalo AK, Proulx ST, Karaman S, Aebischer D, Martino S, Jost M, Schneider N, Bry M, Detmar M. VEGF-C and VEGF-D blockade inhibits inflammatory skin carcinogenesis. Cancer Res 2013;73(14):4212–4221.
   PubMed Web of Science ®Google Scholar
• Kijowski J, Baj-Krzyworzeka M, Majka M, Reca R, Marquez LA, Christofidou-Solomidou M, Janowska-Wieczorek A, Ratajczak MZ. The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells. Stem Cells 2001;19(5): 453–466.
   PubMed Web of Science ®Google Scholar
• Chen JC, Chang YW, Hong CC, Yu YH, Su JL. The Role of the VEGF-C/VEGFRs Axis in Tumor Progression and Therapy. Int J Mol Sci 2013;14(1):88–107.
   Web of Science ®Google Scholar
• Kirkin V, Thiele W, Baumann P, Mazitschek R, Rohde K, Fellbrich G, Weich H, Waltenberger J, Giannis A, Sleeman JP. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer 2004;112(6):986–993.
   PubMed Web of Science ®Google Scholar
• Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci 2008;65(17):2740–2751.
   PubMed Web of Science ®Google Scholar
• Breslin JW, Yuan SY, Wu MH. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol 2007;5(2):105–113.
   PubMedGoogle Scholar
• Lim JJ, Yang K, Taylor-Harding B, Wiedemeyer WR, Buckanovich RJ. VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia 2014;16(4):343–353 e1–2.
   PubMed Web of Science ®Google Scholar
• Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood 2008;112(5):1740–1749.
   PubMed Web of Science ®Google Scholar
• Lee JY, Park S, Kim DC, Yoon JH, Shin SH, Min WS, Kim HJ. A VEGFR-3 antagonist increases IFN-gamma expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol 2013;33(4):826–837.
   PubMed Web of Science ®Google Scholar
• Park JH, Shin YJ, Riew TR, Lee MY. The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3beta signaling pathways. PLoS One 2014;9(9):e109055.
   PubMed Web of Science ®Google Scholar
• Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol 2010;36(12):1172–1179.
   PubMed Web of Science ®Google Scholar
• Yu JW, Wu SH, Lu RQ, Wu JG, Ni XC, Zhou GC, Jiang HG, Zheng LH, Li XQ, Du GY, Jiang BJ. Expression and significances of contactin-1 in human gastric cancer. Gastroenterol Res Pract 2013;2013:210205.
   PubMedGoogle Scholar
• Chen H, Ding X, Gao Y, Jiang X, Liu X, Chen Y, Gao J, Zhou X, Cai Z, Sun Q. Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3. MAbs 2013;5(6):956–961.
   PubMed Web of Science ®Google Scholar
• Yang H, Kim C, Kim MJ, Schwendener RA, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY. Soluble vascular endothelial growth factor receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder cancer. Mol Cancer 2011;10:36.
   PubMed Web of Science ®Google Scholar
• Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S. Antiangiogenic gene therapy with soluble VEGFR-1, −2, and −3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther 2009;17(2):278–284.
   PubMed Web of Science ®Google Scholar